<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:googleplay="http://www.google.com/schemas/play-podcasts/1.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:media="http://search.yahoo.com/mrss/" xmlns:podcast="https://podcastindex.org/namespace/1.0">
  <channel>
    <atom:link href="https://feeds.simplecast.com/EEfzGaQJ" rel="self" title="MP3 Audio" type="application/atom+xml"/>
    <atom:link href="https://simplecast.superfeedr.com" rel="hub" xmlns="http://www.w3.org/2005/Atom"/>
    <generator>https://simplecast.com</generator>
    <title>The Real-World Evidence is Clear</title>
    <description>The Real-World Evidence is Clear is a thought leadership podcast series from Thermo Fisher Scientific, the world leader in serving science, exploring the real-world questions shaping evidence generation, market access, health economics, and patient-centered research. Featuring expert conversations with internal specialists and external leaders from across industry, regulation and academia, the series examines timely issues with a technical, practical, and non-promotional lens. Designed for professionals working in clinical research, HEOR, market access, and related fields, the podcast focuses on rigorous discussion, credible insight, and the evolving role of data in supporting better healthcare decisions.</description>
    <copyright>2026 Thermo Fisher Scientific</copyright>
    <language>en</language>
    <pubDate>Tue, 28 Apr 2026 10:20:12 +0000</pubDate>
    <lastBuildDate>Tue, 28 Apr 2026 12:04:30 +0000</lastBuildDate>
    <image>
      <link>https://the-real-world-evidence-is-clear.simplecast.com</link>
      <title>The Real-World Evidence is Clear</title>
      <url>https://image.simplecastcdn.com/images/ac5fb8c8-8a3c-4ec8-b85e-218fdfedf389/573b355d-c579-41f0-8bd7-2240d36ca8a5/3000x3000/rwe-podcastcoverart.jpg?aid=rss_feed</url>
    </image>
    <link>https://the-real-world-evidence-is-clear.simplecast.com</link>
    <itunes:type>episodic</itunes:type>
    <itunes:summary>The Real-World Evidence is Clear is a thought leadership podcast series from Thermo Fisher Scientific, the world leader in serving science, exploring the real-world questions shaping evidence generation, market access, health economics, and patient-centered research. Featuring expert conversations with internal specialists and external leaders from across industry, regulation and academia, the series examines timely issues with a technical, practical, and non-promotional lens. Designed for professionals working in clinical research, HEOR, market access, and related fields, the podcast focuses on rigorous discussion, credible insight, and the evolving role of data in supporting better healthcare decisions.</itunes:summary>
    <itunes:author>Thermo Fisher Scientific</itunes:author>
    <itunes:explicit>false</itunes:explicit>
    <itunes:image href="https://image.simplecastcdn.com/images/ac5fb8c8-8a3c-4ec8-b85e-218fdfedf389/573b355d-c579-41f0-8bd7-2240d36ca8a5/3000x3000/rwe-podcastcoverart.jpg?aid=rss_feed"/>
    <itunes:new-feed-url>https://feeds.simplecast.com/EEfzGaQJ</itunes:new-feed-url>
    <itunes:keywords>clinical research,clinical trials,evidence generation,health economics,health technology assessment,heath economics and market access,heor,hta,life sciences thought leadership,patient-centered evidence,real-world evidence,regulatory-grade data,rwe</itunes:keywords>
    <itunes:owner>
      <itunes:name>Thermo Fisher Scientific</itunes:name>
      <itunes:email>mike.lawrence@thermofisher.com</itunes:email>
    </itunes:owner>
    <itunes:category text="Science">
      <itunes:category text="Life Sciences"/>
    </itunes:category>
    <item>
      <guid isPermaLink="false">4303b407-7d37-4561-a7e0-9fb34228bea5</guid>
      <title>Better or Just Faster? AI&apos;s Real Role in Health Technology Assessment</title>
      <description><![CDATA[<p>This first episode of Thermo Fisher Scientific's The Real-World Evidence is Clear podcast features <strong>Matthew Bending</strong> (host), Vice President, Global Head of Health Economics & Market Access, Thermo Fisher Scientific; <strong>Gianluca Baio</strong>, Professor of Statistics and Health Economics, UCL; <strong>Rachael Hunter</strong>, Professor of Health Economics, UCL; and <strong>Jack Ishak</strong>, Vice President, Statistical Methodology & Innovation, Thermo Fisher Scientific.</p>
<p>AI is moving quickly into health technology assessment, but this episode focuses on the bigger question: is trust in the output keeping pace with the speed of adoption?</p>
<p>The discussion makes clear that in HTA, faster is only useful if the evidence remains robust, credible, and ready for scrutiny. The panel argues that AI should not be judged only by whether it saves time, but by whether it helps produce work that decision-makers can trust. That matters in a field where plausible is not enough and methodological rigor is everything.</p>
<p>A recurring theme is that AI can shift effort rather than remove it. Professor Rachael Hunter describes AI-assisted work that looked reasonable on the surface but still required detailed checking and correction. Jack Ishak makes a similar point in literature reviews: AI may help with abstract screening, but it is less reliable when extracting detailed evidence. Time saved early can easily be lost later in validation and quality control.</p>
<p>The episode also explores the risk of AI creating an illusion of competence. Professor Gianluca Baio argues that AI is most useful when it supports people who already understand the underlying methods. Used well, it can accelerate expert work. Used badly, it can allow people to move quickly without recognising when the output is flawed.</p>
<p>Transparency is another major theme. As AI becomes more common in HTA workflows, regulators and reviewers will likely expect clearer documentation of how it was used, what human oversight was applied, and how outputs were validated. The panel also considers who will shape the rules, with consultancies likely to move fastest, academia more cautiously, and HTA agencies remaining the ultimate gatekeepers.</p>
<p>Overall, the episode presents AI in HTA as promising but still unresolved. Adoption is already happening. The real challenge now is building the standards, governance, and skills needed to ensure that faster workflows still produce evidence that is rigorous, transparent, and trusted.</p>
]]></description>
      <pubDate>Tue, 28 Apr 2026 10:20:12 +0000</pubDate>
      <author>mike.lawrence@thermofisher.com (Matthew Bending, Gianluca Baio, Rachael Hunter, Jack Ishak)</author>
      <link>https://the-real-world-evidence-is-clear.simplecast.com/episodes/better-or-just-faster-ais-real-role-in-health-technology-assessment-tRIZdkxI</link>
      <media:thumbnail height="720" url="https://image.simplecastcdn.com/images/ac5fb8c8-8a3c-4ec8-b85e-218fdfedf389/94377870-1dfb-4f45-9245-97ab9ea2c1aa/rwe_linkedinpost.png" width="1280"/>
      <content:encoded><![CDATA[<p>This first episode of Thermo Fisher Scientific's The Real-World Evidence is Clear podcast features <strong>Matthew Bending</strong> (host), Vice President, Global Head of Health Economics & Market Access, Thermo Fisher Scientific; <strong>Gianluca Baio</strong>, Professor of Statistics and Health Economics, UCL; <strong>Rachael Hunter</strong>, Professor of Health Economics, UCL; and <strong>Jack Ishak</strong>, Vice President, Statistical Methodology & Innovation, Thermo Fisher Scientific.</p>
<p>AI is moving quickly into health technology assessment, but this episode focuses on the bigger question: is trust in the output keeping pace with the speed of adoption?</p>
<p>The discussion makes clear that in HTA, faster is only useful if the evidence remains robust, credible, and ready for scrutiny. The panel argues that AI should not be judged only by whether it saves time, but by whether it helps produce work that decision-makers can trust. That matters in a field where plausible is not enough and methodological rigor is everything.</p>
<p>A recurring theme is that AI can shift effort rather than remove it. Professor Rachael Hunter describes AI-assisted work that looked reasonable on the surface but still required detailed checking and correction. Jack Ishak makes a similar point in literature reviews: AI may help with abstract screening, but it is less reliable when extracting detailed evidence. Time saved early can easily be lost later in validation and quality control.</p>
<p>The episode also explores the risk of AI creating an illusion of competence. Professor Gianluca Baio argues that AI is most useful when it supports people who already understand the underlying methods. Used well, it can accelerate expert work. Used badly, it can allow people to move quickly without recognising when the output is flawed.</p>
<p>Transparency is another major theme. As AI becomes more common in HTA workflows, regulators and reviewers will likely expect clearer documentation of how it was used, what human oversight was applied, and how outputs were validated. The panel also considers who will shape the rules, with consultancies likely to move fastest, academia more cautiously, and HTA agencies remaining the ultimate gatekeepers.</p>
<p>Overall, the episode presents AI in HTA as promising but still unresolved. Adoption is already happening. The real challenge now is building the standards, governance, and skills needed to ensure that faster workflows still produce evidence that is rigorous, transparent, and trusted.</p>
]]></content:encoded>
      <enclosure length="36308575" type="audio/mpeg" url="https://cdn.simplecast.com/media/audio/transcoded/3790f2f6-a03b-47be-8cde-74091cd8a453/6a960dc8-8bbf-45c0-a7ba-649683054f23/episodes/audio/group/15b9ae30-6325-47fb-9d2a-d41c636e438f/group-item/5f52cdb6-e0e1-4707-aeb8-a4d76ef8f41a/128_default_tc.mp3?aid=rss_feed&amp;feed=EEfzGaQJ"/>
      <itunes:title>Better or Just Faster? AI&apos;s Real Role in Health Technology Assessment</itunes:title>
      <itunes:author>Matthew Bending, Gianluca Baio, Rachael Hunter, Jack Ishak</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/ac5fb8c8-8a3c-4ec8-b85e-218fdfedf389/f6540090-6a89-4165-b598-cac7643cfa34/3000x3000/rwe_episode_1.jpg?aid=rss_feed"/>
      <itunes:duration>00:37:49</itunes:duration>
      <itunes:summary>This episode explores the impact of AI on health technology assessment (HTA), focusing on whether AI makes work faster or better, and how to ensure credibility, transparency, and responsible use. Featuring Professor Gianluca Baio and Professor Rachael Hunter from University College London (UCL) and Matthew Bending and Jack Ishak from Thermo Fisher Scientific, the discussion covers validation, accreditation, industry roles, and future challenges in AI-enabled HTA.</itunes:summary>
      <itunes:subtitle>This episode explores the impact of AI on health technology assessment (HTA), focusing on whether AI makes work faster or better, and how to ensure credibility, transparency, and responsible use. Featuring Professor Gianluca Baio and Professor Rachael Hunter from University College London (UCL) and Matthew Bending and Jack Ishak from Thermo Fisher Scientific, the discussion covers validation, accreditation, industry roles, and future challenges in AI-enabled HTA.</itunes:subtitle>
      <itunes:keywords>hta, healthcare regulation, healthcare innovation, health economics, artificial intelligence in healthcare, ai in healthcare, regulatory standards, ai validation, health technology assessment, ai</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>1</itunes:episode>
    </item>
  </channel>
</rss>